MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Zai Lab Ltd ADR

Fechado

SetorSaúde

35.46 0.74

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.84

Máximo

35.48

Indicadores-chave

By Trading Economics

Rendimento

33M

-48M

Vendas

-2.6M

106M

Margem de lucro

-45.487

Funcionários

1,869

EBITDA

19M

-56M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+64.93% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

475M

3.9B

Abertura anterior

34.72

Fecho anterior

35.46

Sentimento de Notícias

By Acuity

50%

50%

154 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Zai Lab Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de jul. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 de jul. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 de jul. de 2025, 23:05 UTC

Conversa de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 de jul. de 2025, 21:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de jul. de 2025, 21:36 UTC

Conversa de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

15 de jul. de 2025, 20:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 de jul. de 2025, 20:07 UTC

Ganhos

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 de jul. de 2025, 20:06 UTC

Conversa de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 de jul. de 2025, 19:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

15 de jul. de 2025, 19:54 UTC

Conversa de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 de jul. de 2025, 19:38 UTC

Conversa de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 de jul. de 2025, 19:09 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 de jul. de 2025, 19:07 UTC

Conversa de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 de jul. de 2025, 19:03 UTC

Conversa de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 de jul. de 2025, 18:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 de jul. de 2025, 18:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 de jul. de 2025, 18:13 UTC

Conversa de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 de jul. de 2025, 17:40 UTC

Conversa de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 de jul. de 2025, 17:40 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de jul. de 2025, 17:25 UTC

Aquisições, Fusões, Aquisições de Empresas

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 de jul. de 2025, 17:24 UTC

Conversa de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 de jul. de 2025, 16:49 UTC

Conversa de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

15 de jul. de 2025, 15:42 UTC

Conversa de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparação entre Pares

Variação de preço

Zai Lab Ltd ADR Previsão

Preço-alvo

By TipRanks

64.93% parte superior

Previsão para 12 meses

Média 58.04 USD  64.93%

Máximo 75 USD

Mínimo 38.2 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Zai Lab Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

5

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

28.13 / 31.12Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

154 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.